이네이트 파마(IPHA)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $1.93 (+1.05%), 시가총액 $0.19B, 52주 최저~최고 $1.17 ~ $2.38.
Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma; IPH4502, a novel and differentiated topoisomerase I inhibitor ADC conjugated to exatecan targeting Nectin-4; and Monalizumab, a dual checkpoint inhibitor that targets T Cells and NK Cells. It also develops IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive
이네이트 파마의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
이네이트 파마의 현재 주가는 $1.93 (+1.05%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
이네이트 파마의 시가총액은 약 $0.19B입니다.
Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3